LOVFF (Cannara Biotech) Shareholder Yield % : 1.77% (As of Feb. 2026)


LOVFF Cannara Biotech Inc LOVFF
84 GF Score
Price $1.18
GF Value $1.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cannara Biotech Shareholder Yield %?

Cannara Biotech LOVFF -4.84% 84 Shareholder Yield % is 1.77% as of Feb. 2026. GuruFocus rates LOVFF with a GF Score™ of 84/100 and a GF Value™ of $1.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 969 Drug Manufacturers companies, Cannara Biotech ranks better than 62.75% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Cannara Biotech's Shareholder Yield % was 1.77%.


Cannara Biotech  (OTCPK:LOVFF) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Cannara Biotech Shareholder Yield % Related Terms


Cannara Biotech Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Shareholder Yield % Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Shareholder Yield %
Get a 7-Day Free Trial -18.92 -15.70 -10.57 -5.03 1.28

Cannara Biotech Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 -0.19 1.28 3.57 1.58

LOVFF vs ZTS, UTHR: Shareholder Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech Shareholder Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Shareholder Yield % falls into.


LOVFF
84GF Score
Cannara Biotech Inc LOVFF
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Shareholder Yield % Calculation

Cannara Biotech's Shareholder Yield % for the quarter that ended in Feb. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-3.37 %+5.02 %
=1.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 1.77% mean?
Cannara Biotech (LOVFF) has a Shareholder Yield % of 1.77% as of Feb. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cannara Biotech and its competitors. According to the industry distribution chart, Cannara Biotech ranks #361 out of 969 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is Cannara Biotech's Shareholder Yield % too high?
Cannara Biotech's current Shareholder Yield % is 1.77%. The Drug Manufacturers industry median Shareholder Yield % is 0.34. Cannara Biotech's value of 1.77% is 420.6% above this industry median. Based on the distribution chart, Cannara Biotech ranks #361 out of 969 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #361 out of 969 companies for Shareholder Yield %. This puts Cannara Biotech in the upper half of its industry. The industry median Shareholder Yield % is 0.34. Cannara Biotech's value of 1.77% is 420.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.34, based on 969 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Shareholder Yield % of 1.77% is 420.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Shareholder Yield % is 1.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.18, compared to a current price of $1.18 — trading right at its estimated fair value. The current Shareholder Yield % is 1.77% and 420.6% above the Drug Manufacturers industry median of 0.34. Cannara Biotech's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Shareholder Yield % is 1.77% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued. The current stock price of $1.18 is trading 0% below its estimated GF Value™ of $1.18. GuruFocus considers Cannara Biotech to be Fairly Valued.

Key valuation signals for LOVFF:

  • Shareholder Yield %: 1.77%
  • GF Value™: $1.18 vs. price of $1.18 (0% below fair value)
  • GF Score™: 84/100 with 4 warning signs
  • Industry Position: 420.6% above the Drug Manufacturers median (#361 of 969)

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
84GF Score

Get the complete analysis for LOVFF

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price
$1.18
GF Value